MORPHEUS-EC: A phase Ib/II open-label, randomized study of first-line tiragolumab (tira) + atezolizumab (atezo) + chemotherapy (CT) in patients (pts) with esophageal cancer (EC).

Sun, Jong-MuJong-MuSunChao, YeeYeeChaoKim, Sung-BaeSung-BaeKimRha, Sun YoungSun YoungRhaEvans, T.R. JeffryT.R. JeffryEvansStrickland, AndrewAndrewStricklandWainberg, Zev A.Zev A.WainbergChau, IanIanChauPelles-Avraham, SharonSharonPelles-AvrahamAjani, Jaffer A.Jaffer A.AjaniMalhotra, RituRituMalhotraLiu, QingyuanQingyuanLiuLi, SijingSijingLiCha, EdwardEdwardChaRahalkar, SwapnaSwapnaRahalkarAllen, SimonSimonAllenCHIH-HUNG HSU2026-01-232026-01-232024-01-200732183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/735542falseMORPHEUS-EC: A phase Ib/II open-label, randomized study of first-line tiragolumab (tira) + atezolizumab (atezo) + chemotherapy (CT) in patients (pts) with esophageal cancer (EC).review article2-s2.0-105024529810